Zamora Laura, Gatell José María
Servicio De Infecciones, Hospital Clínic, Barcelona, España.
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:14-21. doi: 10.1016/S0213-005X(08)76615-1.
Atazanavir is a new azapeptide protease inhibitor with a remarkable pharmacokinetic profile, which means it can be administered in only two capsules once per day in combination with other antiretrovirals. Its strong antiviral efficacy is also accompanied by an excellent tolerance profile and no significant increase in cholesterol and triglyceride levels. The immunological and virological response obtained with atazanavir or atazanavir/ritonavir, in naive patients as well as in patients with previous virological failure with other protease inhibitors, is excellent. Atazanavir is an attractive drug for therapeutic simplification. Besides maintaining virological suppression, patients who change from other PI to atazanavir experience reductions in total cholesterol, HDL cholesterol and triglycerides. Preliminary data suggest that simplified maintenance treatment with atazanavir/ritonavir in monotherapy, can effectively maintain virological suppression in selected patients.
阿扎那韦是一种新型氮杂环肽蛋白酶抑制剂，具有显著的药代动力学特征，这意味着它可以与其他抗逆转录病毒药物联合使用，每天仅服用两粒胶囊。它强大的抗病毒疗效还伴随着良好的耐受性，且胆固醇和甘油三酯水平无显著升高。在初治患者以及先前使用其他蛋白酶抑制剂出现病毒学失败的患者中，使用阿扎那韦或阿扎那韦/利托那韦获得的免疫和病毒学反应都非常出色。阿扎那韦是一种有助于简化治疗的有吸引力的药物。除了维持病毒学抑制外，从其他蛋白酶抑制剂转换为阿扎那韦的患者，其总胆固醇、高密度脂蛋白胆固醇和甘油三酯水平会降低。初步数据表明，在单药治疗中使用阿扎那韦/利托那韦进行简化维持治疗，可以有效维持部分患者的病毒学抑制。
